Market Views – Page 10 – media

Zymeworks and Celgene Expand Bispecific Antibody Collaboration

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ Azymetric™ platform.
- Source: ir.zymeworks
- 659
- April 27, 2018
bispecific antibody therapeutics Celgene Market Views
Third Rock Ventures Launches Cedilla Therapeutics with $56 Million Investment to Target Protein Stability Using Small Molecule Therapeutics

Company is targeting upstream aspects of native protein degradation pathways to develop new therapies for cancer
- Source: drugdu
- 710
- April 26, 2018
Market Views Series small molecule
Takeda reaches preliminary deal to buy Shire for close to $65B

Takeda has upped its offer to buy Shire $SHPG for a mix of stock and cash worth close to $65 billion, which is good enough for the Lexington, MA-based biotech to extend the deadline on their talks to May 8 after determining they were close to finalizing a pact.
- Source: endpts
- 673
- April 25, 2018
Lexington Market Views Shire Takeda
Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies

- A CD19 CAR with novel targeting properties designed to reduce cytokine release syndrome –
- Source: autolus
- 592
- April 25, 2018
B-cell malignancies Market Views T-cell therapies
UCB snags an NDA-ready epilepsy drug from Proximagen in $370M deal

UCB is beefing up its pipeline of epilepsy drugs with an NDA-ready therapy from Proximagen. The Belgian company has agreed to buy their nasal spray therapy USL261, designed as a rescue therapy for acute repetitive seizures, for $150 million in cash and another $220 million in sales and regulatory milestones.
- Source: endpts
- 587
- April 25, 2018
acute repetitive seizures Market Views Proximagen UCB
‘Orangeworm’ hacking campaign hits X-ray and MRI machines

Malware from a newly disclosed hacking campaign has infected the networks of multinational health care companies, including some X-ray and MRI machines, cybersecurity firm Symantec warned Monday.
- Source: CyberScoop
- 744
- April 25, 2018
cybersecurity Market Views
New partnership announced to prepare Australian GPs for the national expansion of My Health Record

GPs will be actively involved in the delivery of the Federal Government’s My Health Record, with a new partnership designed to train doctors in the use of the national online health information repository and prepare them to answer patients’ questions.
- Source: Healthcare IT
- 561
- April 25, 2018
healthcare Market Views
Inventiva Raises €35.5 Million Through A Capital Increase With European And US Investors

Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announces the successful completion of the issuance of 5,572,500 new ordinary shares without preferential subscription rights (the "New Shares") for a total gross proceeds of approximately €35.5 million by means of a private placement reserved to a specified category of investors as described below (the "Reserved Offering"). The Reserved Offering was conducted by Jefferies International Limited, acting as Global Coordinator and Joint Bookrunner, and Société Générale Corporate & Investment Banking and Gilbert Dupont acting as Joint Bookrunners (together with the Global Coordinator and Joint Bookrunner, the "Managers"). Namsen Capital acted as Inventiva's Capital Markets Advisor.
- Source: drugdu
- 615
- April 24, 2018
Market Views MPS NASH Series SSc
How health apps factor into a $950B ecosystem

Highlighting the ubiquity and importance of smartphones across multiple industries, a new report by ACT | The App Association indicated that two out of three businesses utilize enterprise apps. And many of those opportunities are rising up throughout the healthcare industry.
- Source: Fierce Healthcare
- 643
- April 24, 2018
healthcare Market Views mHealth
Allergan swoops in as Takeda’s third Shire bid falls short at $61B

Three of Takeda’s anticipated Shire buyout bids have already been rejected—and now, the Japanese drugmaker might just lose out to a competing bidder. Allergan, for instance, is already in talks for a buy.
- Source: fiercepharma
- 517
- April 23, 2018
drugmaker Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.